Lunai Bioworks Reports $178 Million Net Loss and Faces Financial Challenges

Lunai Bioworks Inc., formerly known as Renovaro Inc., reported significant financial challenges in its recent 10-K filing for the fiscal year ending June 30, 2025. The company recorded a net loss of $178 million, a 101% increase from the previous year's loss of $88.4 million. This increase was primarily driven by a substantial goodwill impairment of approximately $170.4 million, reflecting the company's ongoing struggles to secure funding and develop its technologies. Total operating expenses surged to $189 million, up 131% from $81.6 million in the prior year, largely due to the aforementioned impairment and a decrease in research and development expenses.

In terms of operational changes, Lunai Bioworks underwent a strategic shift following the acquisitions of Renovaro Cube and BioSymetrics, which occurred in February 2024 and April 2025, respectively. These acquisitions aimed to enhance the company's capabilities in artificial intelligence-driven diagnostics and biomarker discovery. However, the company faced setbacks, including the bankruptcy of its subsidiary, GEDi Cube B.V., which was declared bankrupt in September 2025, leading to a material impairment of its assets.

The company reported a decrease in cash reserves, with only $92,700 available as of June 30, 2025, down from $220,467 the previous year. This decline in liquidity raises concerns about the company's ability to continue operations without additional financing. Lunai Bioworks has indicated that it will need to secure further funding to support its research and development efforts, as well as to cover operational costs. The company has historically relied on equity and debt financing, but the ability to raise capital remains uncertain.

As of the end of the reporting period, Lunai Bioworks had 29 full-time employees, a reduction in workforce as part of its strategy to streamline operations. The company is focused on developing its AI-driven cancer diagnostics platform and aims to expand its market presence. However, the outlook remains cautious, with management acknowledging substantial doubt about the company's ability to continue as a going concern without securing additional funding. The company plans to utilize any future funding to satisfy existing obligations and support the commercialization of its products.

In summary, Lunai Bioworks Inc. is navigating a challenging financial landscape marked by significant losses, operational restructuring, and the need for additional capital to sustain its business. The company's future will depend on its ability to successfully develop its product candidates and secure the necessary funding to continue operations.